S&P 500   4,351.19 (+0.49%)
DOW   34,096.77 (+0.08%)
QQQ   361.18 (+0.93%)
AAPL   176.49 (+1.47%)
MSFT   320.57 (+0.33%)
META   304.45 (+2.95%)
GOOGL   131.68 (+0.95%)
AMZN   131.47 (+1.65%)
TSLA   255.94 (+0.09%)
NVDA   419.63 (+2.31%)
NIO   8.60 (+1.78%)
BABA   88.47 (+5.18%)
AMD   98.26 (+2.24%)
T   15.12 (-1.24%)
F   12.65 (+3.69%)
MU   69.20 (+1.91%)
CGC   0.82 (+7.27%)
GE   112.85 (-0.12%)
DIS   82.24 (-0.59%)
AMC   7.87 (+2.21%)
PFE   32.72 (-0.40%)
PYPL   58.71 (+0.15%)
NFLX   384.28 (+0.03%)
S&P 500   4,351.19 (+0.49%)
DOW   34,096.77 (+0.08%)
QQQ   361.18 (+0.93%)
AAPL   176.49 (+1.47%)
MSFT   320.57 (+0.33%)
META   304.45 (+2.95%)
GOOGL   131.68 (+0.95%)
AMZN   131.47 (+1.65%)
TSLA   255.94 (+0.09%)
NVDA   419.63 (+2.31%)
NIO   8.60 (+1.78%)
BABA   88.47 (+5.18%)
AMD   98.26 (+2.24%)
T   15.12 (-1.24%)
F   12.65 (+3.69%)
MU   69.20 (+1.91%)
CGC   0.82 (+7.27%)
GE   112.85 (-0.12%)
DIS   82.24 (-0.59%)
AMC   7.87 (+2.21%)
PFE   32.72 (-0.40%)
PYPL   58.71 (+0.15%)
NFLX   384.28 (+0.03%)
S&P 500   4,351.19 (+0.49%)
DOW   34,096.77 (+0.08%)
QQQ   361.18 (+0.93%)
AAPL   176.49 (+1.47%)
MSFT   320.57 (+0.33%)
META   304.45 (+2.95%)
GOOGL   131.68 (+0.95%)
AMZN   131.47 (+1.65%)
TSLA   255.94 (+0.09%)
NVDA   419.63 (+2.31%)
NIO   8.60 (+1.78%)
BABA   88.47 (+5.18%)
AMD   98.26 (+2.24%)
T   15.12 (-1.24%)
F   12.65 (+3.69%)
MU   69.20 (+1.91%)
CGC   0.82 (+7.27%)
GE   112.85 (-0.12%)
DIS   82.24 (-0.59%)
AMC   7.87 (+2.21%)
PFE   32.72 (-0.40%)
PYPL   58.71 (+0.15%)
NFLX   384.28 (+0.03%)
S&P 500   4,351.19 (+0.49%)
DOW   34,096.77 (+0.08%)
QQQ   361.18 (+0.93%)
AAPL   176.49 (+1.47%)
MSFT   320.57 (+0.33%)
META   304.45 (+2.95%)
GOOGL   131.68 (+0.95%)
AMZN   131.47 (+1.65%)
TSLA   255.94 (+0.09%)
NVDA   419.63 (+2.31%)
NIO   8.60 (+1.78%)
BABA   88.47 (+5.18%)
AMD   98.26 (+2.24%)
T   15.12 (-1.24%)
F   12.65 (+3.69%)
MU   69.20 (+1.91%)
CGC   0.82 (+7.27%)
GE   112.85 (-0.12%)
DIS   82.24 (-0.59%)
AMC   7.87 (+2.21%)
PFE   32.72 (-0.40%)
PYPL   58.71 (+0.15%)
NFLX   384.28 (+0.03%)
NASDAQ:ZLAB

Zai Lab (ZLAB) Stock Forecast, Price & News

$24.65
+0.67 (+2.79%)
(As of 10:59 AM ET)
Compare
Today's Range
$24.41
$25.23
50-Day Range
$22.72
$31.49
52-Week Range
$20.98
$49.81
Volume
41,157 shs
Average Volume
613,207 shs
Market Capitalization
$2.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$83.10

Zai Lab MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
246.5% Upside
$83.10 Price Target
Short Interest
Bearish
3.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.05mentions of Zai Lab in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.75) to ($2.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

797th out of 965 stocks

Pharmaceutical Preparations Industry

377th out of 450 stocks


ZLAB stock logo

About Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.

ZLAB Price History

ZLAB Stock News Headlines

This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Zai Lab Stock: De-Risking Through Market Tapping
Pre-market Movers: HSDT, UPTD, ADTX, RENB, MLGO…
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Zai Lab (ZLAB) Receives a Buy from Bank of America Securities
Zai Lab: LUNAR Trial Paves Way For New Therapies
Jefferies Reaffirms Their Buy Rating on Zai Lab (ZLAB)
See More Headlines
Receive ZLAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

ZLAB Company Calendar

Last Earnings
8/07/2023
Today
9/22/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ZLAB
Employees
2,036
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$83.10
High Stock Price Forecast
$130.00
Low Stock Price Forecast
$62.50
Forecasted Upside/Downside
+246.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-443,290,000.00
Net Margins
-156.07%
Pretax Margin
-156.07%

Debt

Sales & Book Value

Annual Sales
$215.04 million
Book Value
$10.68 per share

Miscellaneous

Free Float
93,670,000
Market Cap
$2.37 billion
Optionable
Optionable
Beta
1.12
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Ying Du Ph.D. (Age 57)
    Founder, Chairperson & CEO
    Comp: $1.67M
  • Mr. Joshua L. Smiley (Age 53)
    Pres & COO
    Comp: $647.11k
  • Dr. Rafael G. Amado M.D. (Age 59)
    Pres and Head of Global Oncology R&D
    Comp: $477k
  • Dr. Harald Reinhart M.D. (Age 71)
    Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases
    Comp: $923.33k
  • Dr. Yajing Chen Ph.D.
    Chief Financial Officer
  • Dr. Peter Huang Ph.D.
    Chief Scientific Officer
  • Mr. Frazor Titus Edmondson III (Age 57)
    J.D., Chief Legal Officer & Corp. Sec.
  • Ms. Ann E. Beasley J.D.
    Chief Compliance Officer
  • Dr. Ning Xu M.D. (Age 58)
    Exec. VP & Head of Clinical Operations
  • Dr. Jonathan J. Wang MBA (Age 41)
    Ph.D., Chief Bus. Officer













ZLAB Stock - Frequently Asked Questions

Should I buy or sell Zai Lab stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings
or view top-rated stocks.

What is Zai Lab's stock price forecast for 2023?

3 analysts have issued 12 month price targets for Zai Lab's stock. Their ZLAB share price forecasts range from $62.50 to $130.00. On average, they predict the company's stock price to reach $83.10 in the next year. This suggests a possible upside of 246.5% from the stock's current price.
View analysts price targets for ZLAB
or view top-rated stocks among Wall Street analysts.

How have ZLAB shares performed in 2023?

Zai Lab's stock was trading at $30.70 at the start of the year. Since then, ZLAB shares have decreased by 21.9% and is now trading at $23.98.
View the best growth stocks for 2023 here
.

When is Zai Lab's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our ZLAB earnings forecast
.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) issued its quarterly earnings data on Monday, August, 7th. The company reported ($1.25) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by $0.51. The company had revenue of $68.86 million for the quarter, compared to analyst estimates of $71.40 million. Zai Lab had a negative net margin of 156.07% and a negative trailing twelve-month return on equity of 38.48%.

What guidance has Zai Lab issued on next quarter's earnings?

Zai Lab issued an update on its second quarter earnings guidance on Monday, August, 7th. The company provided earnings per share (EPS) guidance of ($1.25) for the period, compared to the consensus EPS estimate of ($0.79). The company issued revenue guidance of $68.9, compared to the consensus revenue estimate of $70.48 million.

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Capital World Investors (5.31%), Segantii Capital Management Ltd (1.82%), Genesis Investment Management LLP (1.37%), Rock Springs Capital Management LP (1.24%), Capital International Investors (0.98%) and Clearbridge Investments LLC (0.82%). Insiders that own company stock include Frazor Titus Edmondson III, Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis and Ying Du.
View institutional ownership trends
.

How do I buy shares of Zai Lab?

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $23.98.

How much money does Zai Lab make?

Zai Lab (NASDAQ:ZLAB) has a market capitalization of $2.37 billion and generates $215.04 million in revenue each year. The company earns $-443,290,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis.

How many employees does Zai Lab have?

The company employs 2,036 workers across the globe.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for the company is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570.

This page (NASDAQ:ZLAB) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -